Review summary
Teaching objective: Evaluation and management of lower urinary tract symptoms with urinary retention in a 79-year-old man, on the AUA benign prostatic hyperplasia guideline (2021, amended 2023), the AUA white paper on nonneurogenic chronic urinary retention, and the CMID benign prostatic hyperplasia monograph: the IPSS, post-void residual, urinalysis and culture, creatinine and kidney ultrasound for obstruction, PSA with shared decision-making about what it means at his age, an indwelling catheter with catheter-associated infection prevention and treatment (IDSA 2009), an alpha-blocker before a trial without catheter, a 5-alpha-reductase inhibitor for a large prostate, surgical options (laser enucleation, transurethral resection, and less invasive procedures such as prostatic artery embolization) weighed against frailty, a geriatric assessment (falls with alpha-blockers, delirium risk, cognition) with the AGS Beers Criteria 2023, a goals-of-care conversation, and his own values about surgery and his traditional remedies, recorded in his own terms and respected.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| 7 May 1861 | Born in the Jorasanko mansion, Calcutta. | CLM-0001 |
| 22 December 1901 | His school at Santiniketan begins formally. | CLM-0003 |
| 1913 | Nobel Prize in Literature. | CLM-0002, CLM-0004 |
| Late 1937 | Loses consciousness; comatose and near death for a time. | CLM-0005 |
| 15 September 1940 | Falls seriously ill at Kalimpong with lower abdominal pain and a severe urinary infection; brought back to Calcutta. | CLM-0006 |
| 1940 to 1941 | Confined to the house by illness; seeks allopathic, homeopathic, and ayurvedic treatment. | CLM-0007, CLM-0008, CLM-0016 |
| 30 July 1941 | Operation at Jorasanko. | CLM-0009, CLM-0010, CLM-0011, CLM-0012, CLM-0014 |
| 7 August 1941 | Dies at Jorasanko, aged 80. | CLM-0013, CLM-0015 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Rabindranath Tagore was born on 7 May 1861 in the Jorasanko mansion in Calcutta, the youngest son of Debendranath Tagore, a leader of the Brahmo Samaj; the name Tagore is the anglicised transliteration of Thakur. | confirmed | Rabindranath Tagore supports Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports |
| D | He was awarded the Nobel Prize in Literature in 1913 "because of his profoundly sensitive, fresh and beautiful verse, by which, with consummate skill, he has made his poetic thought, expressed in his own English words, a part of the literature of the West". | confirmed | The Nobel Prize in Literature 1913: Summary supports Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports |
| D | He started a school at Santiniketan that began formally on 22 December 1901 with five students, and around it he built Visva-Bharati, an unconventional university. | confirmed | History supports Rabindranath Tagore supports Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports |
| D | He was known by the sobriquets Gurudeb, Kobiguru, and Bishwokobi. | confirmed | Rabindranath Tagore supports Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports |
| D | His last five years were marked by chronic pain and two long periods of illness: in late 1937 he lost consciousness and remained comatose and near death for a time, and in late 1940 a similar spell followed, from which he never recovered. The 1937 illness is not further characterized in the sources read. |
confirmed | Rabindranath Tagore supports |
| D | On 15 September 1940, while visiting Kalimpong, he fell seriously ill with severe pain in his lower abdomen; doctors diagnosed a severe urinary tract infection, and he was brought back, unconscious, to Calcutta. The anchor for the synthetic urinary history. |
probable | Dinda A. India pays homage to Tagore on his 75th death anniversary supports Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports |
| D | In the last two years of his life illness confined him to the house, with swollen feet, numbness of the fingers, and frequent fevers; women of his family and household nursed him at home. | confirmed | Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports |
| D | He sought cure in allopathy, homeopathy, and ayurvedic medicine; physicians including Bidhan Chandra Roy and Nilratan Sarkar supervised his treatment; he is reported to have refused surgery despite repeated insistence from his doctors, to have sought a herbal cure, and to have said that he was more afraid of complicated medical treatment than of death. The anchor for the documented preference in the synthetic episode; included with respect. |
probable | Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports Dinda A. India pays homage to Tagore on his 75th death anniversary supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports |
| D | He was very anxious about the operation and asked several times whether it would hurt; a few days before it he asked for a prayer-poem asking not for rescue from danger but for courage in it. | confirmed | Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports |
| D | He was operated on at Jorasanko, on a veranda outside his room made into an operating theatre, on 30 July 1941; one reference work instead says he dictated a poem on 30 July, a day before a scheduled operation. The date is reported inconsistently. |
probable | Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports Dinda A. India pays homage to Tagore on his 75th death anniversary supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports Rabindranath Tagore context |
| R | Doctors reviewing his records for a 2016 exhibition said he had an enlarged prostate that was stopping his urine flow. Retrospective medical reading of his final illness. |
probable | Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports |
| R | Accounts of the operation differ: one says the doctors could not operate on the enlarged prostate and instead performed a bypass to drain the accumulated urine and relieve pain; another says the operation was performed and was successful. The nature of the operation is reported inconsistently. |
disputed | Dinda A. India pays homage to Tagore on his 75th death anniversary supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports |
| R | Present-day doctors believe that infection after the operation led to septicaemia and his death. Retrospective interpretation. |
possible | Dinda A. India pays homage to Tagore on his 75th death anniversary supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports |
| R | A university vice-chancellor said in 2018 that he was suffering from cancer in his prostate; other accounts describe only an enlarged prostate. Not adopted; the synthetic episode makes no cancer diagnosis and does not suggest one. |
disputed | Dinda A. India pays homage to Tagore on his 75th death anniversary supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore context |
| D | He died on 7 August 1941, aged 80, at the Jorasanko house, after a prolonged period of suffering. Record the death as a fact without detail. |
confirmed | Rabindranath Tagore supports Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 supports Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore supports |
| D | He suffered the untimely deaths of his wife and three of his children; he took his daughter Renuka to hill stations in the Himalayas for her recovery from tuberculosis. Family history only. |
confirmed | Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Benign prostatic hyperplasia with severe lower urinary tract symptoms (IPSS 26) and bladder outlet obstruction: prostate about 85 mL on ultrasound, smooth and benign on examination, PSA 4.9 ng/mL (PSA density 0.06) | active | confirmed | both_with_link | CLM-0006, CLM-0011 |
| S | Urinary retention with severe lower urinary tract symptoms (bladder scan 640 mL after voiding) and a raised creatinine, cause under evaluation | resolved | confirmed | active | CLM-0006, CLM-0011 |
| S | Chronic urinary retention from bladder outlet obstruction, low risk once drained (no hydronephrosis; creatinine normal after drainage), managed with an indwelling urethral catheter | resolved | confirmed | active | CLM-0006, CLM-0011 |
| S | Catheter-associated urinary tract infection with fever, without sepsis; resolved | resolved | confirmed | active | CLM-0006 |
| S | Mild frailty (Clinical Frailty Scale 5): slow gait (Timed Up and Go 15 seconds), needs help with heavy housework and travel; cognition normal (Mini-Cog 4) | active | confirmed | active | CLM-0007 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-02-17 | Symptom score [AUASI] | 26 | http://loinc.org · 80891-5 |
| S | 2026-02-17 | If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] | 5 | http://loinc.org · 81090-3 |
| S | 2026-02-17 | US Urinary bladder Volume post void | 640 mL (high) Reference <=100 mL |
http://loinc.org · 98856-8 |
| S | 2026-02-17 | Leukocytes [#/area] in Urine sediment by Microscopy high power field | 3 /[HPF] Reference <=5 /[HPF] |
http://loinc.org · 5821-4 |
| S | 2026-02-17 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-02-17 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-02-17 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-02-17 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-02-17 | Urea nitrogen [Mass/volume] in Serum or Plasma | 27 mg/dL (high) Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-02-17 | Creatinine [Mass/volume] in Serum or Plasma | 1.42 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 50 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-17 | Glucose [Mass/volume] in Serum or Plasma | 97 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-02-17 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 4.9 ng/mL Reference Age-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasteride |
http://loinc.org · 2857-1 |
| S | 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-03-03 | Urea nitrogen [Mass/volume] in Serum or Plasma | 18 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 63 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-03 | Prostate Volume by derived from height, width and length (US) | 85 mL (high) Reference <=30 mL |
http://loinc.org · 15308-0 |
| S | 2026-03-17 | Leukocytes [#/volume] in Blood by Automated count | 13.8 10*3/uL (high) Reference 3.4-9.6 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-17 | Hemoglobin [Mass/volume] in Blood | 13.4 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-17 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-17 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-17 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-03-17 | Urea nitrogen [Mass/volume] in Serum or Plasma | 25 mg/dL (high) Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-03-17 | Creatinine [Mass/volume] in Serum or Plasma | 1.31 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 55 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-17 | Glucose [Mass/volume] in Serum or Plasma | 112 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-17 | Leukocytes [#/area] in Urine sediment by Microscopy high power field | 60 /[HPF] (high) Reference <=5 /[HPF] |
http://loinc.org · 5821-4 |
| S | 2026-03-31 | US Urinary bladder Volume post void | 420 mL (high) Reference <=100 mL |
http://loinc.org · 98856-8 |
| S | 2026-03-31 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-31 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-31 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-03-31 | Urea nitrogen [Mass/volume] in Serum or Plasma | 19 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-03-31 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-31 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 64 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-31 | Glucose [Mass/volume] in Serum or Plasma | 95 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-31 | Total score [Mini-Cog] | 4 | http://loinc.org · 72233-0 |
| S | 2026-06-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-07-14 | US Urinary bladder Volume post void | 150 mL (high) Reference <=100 mL |
http://loinc.org · 98856-8 |
| S | 2026-07-14 | Symptom score [AUASI] | 13 | http://loinc.org · 80891-5 |
| S | 2026-07-14 | If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that [IPSS] | 3 | http://loinc.org · 81090-3 |
| S | 2026-07-14 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-07-14 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-14 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-07-14 | Urea nitrogen [Mass/volume] in Serum or Plasma | 18 mg/dL Reference 8-23 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-14 | Glucose [Mass/volume] in Serum or Plasma | 93 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-14 | Prostate specific Ag [Mass/volume] in Serum or Plasma | 2.6 ng/mL Reference Age-specific upper limit 6.5 ng/mL for 70 to 79 years; halve the expected value on finasteride |
http://loinc.org · 2857-1 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-02-17 | Body height | 183 cm | 8302-2 | S |
| 2026-02-17 | Body weight | 66 kg | 29463-7 | S |
| 2026-02-17 | Body mass index (BMI) [Ratio] | 19.7 kg/m2 | 39156-5 | S |
| 2026-02-17 | Systolic blood pressure | 138 mm[Hg] | 8480-6 | S |
| 2026-02-17 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-02-17 | Heart rate | 76 /min | 8867-4 | S |
| 2026-02-17 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-02-17 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-02-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-03-03 | Body height | 183 cm | 8302-2 | S |
| 2026-03-03 | Body weight | 65.8 kg | 29463-7 | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 19.6 kg/m2 | 39156-5 | S |
| 2026-03-03 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-03-03 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-03-03 | Heart rate | 72 /min | 8867-4 | S |
| 2026-03-03 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-03 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-03-17 | Body height | 183 cm | 8302-2 | S |
| 2026-03-17 | Body weight | 65.1 kg | 29463-7 | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 19.4 kg/m2 | 39156-5 | S |
| 2026-03-17 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-03-17 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-03-17 | Heart rate | 98 /min | 8867-4 | S |
| 2026-03-17 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-03-17 | Body temperature | 38.4 Cel | 8310-5 | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 % | 59408-5 | S |
| 2026-03-31 | Body height | 183 cm | 8302-2 | S |
| 2026-03-31 | Body weight | 65.3 kg | 29463-7 | S |
| 2026-03-31 | Body mass index (BMI) [Ratio] | 19.5 kg/m2 | 39156-5 | S |
| 2026-03-31 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-03-31 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-03-31 | Heart rate | 74 /min | 8867-4 | S |
| 2026-03-31 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-31 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-04-28 | Body height | 183 cm | 8302-2 | S |
| 2026-04-28 | Body weight | 65.6 kg | 29463-7 | S |
| 2026-04-28 | Body mass index (BMI) [Ratio] | 19.6 kg/m2 | 39156-5 | S |
| 2026-04-28 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2026-04-28 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-04-28 | Heart rate | 72 /min | 8867-4 | S |
| 2026-04-28 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-28 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-06-09 | Body height | 183 cm | 8302-2 | S |
| 2026-06-09 | Body weight | 66 kg | 29463-7 | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 19.7 kg/m2 | 39156-5 | S |
| 2026-06-09 | Systolic blood pressure | 132 mm[Hg] | 8480-6 | S |
| 2026-06-09 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-06-09 | Heart rate | 70 /min | 8867-4 | S |
| 2026-06-09 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-09 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-07-14 | Body height | 183 cm | 8302-2 | S |
| 2026-07-14 | Body weight | 66.2 kg | 29463-7 | S |
| 2026-07-14 | Body mass index (BMI) [Ratio] | 19.8 kg/m2 | 39156-5 | S |
| 2026-07-14 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2026-07-14 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-07-14 | Heart rate | 70 /min | 8867-4 | S |
| 2026-07-14 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Poet, writer, composer, and painter; founder of a school and a university in a rural town, where he lives on the campus; still writes every day, dictating when he is tired
- S Widower; lives with family members and is looked after at home by several devoted helpers; none is named in this record
- S Never smoked; no alcohol; no drug use; prefers simple, plain food
- S For the past five months has taken a herbal preparation from a practitioner of traditional Indian medicine (ayurveda), whom he trusts; he hoped it would spare him an operation
- S Supports: his writing, his students and colleagues, his family and helpers, and a daily practice of prayer and quiet; no firearms in the home
Functional status
- S Independent in bathing, dressing, eating, and transfers; walks slowly indoors without an aid; needs help with travel and heavy housework; up four times a night to pass urine, which leaves him tired by day
Mental status
- S Tall, white-bearded, courteous, and articulate, with a dry humor; mood "patient, but tired of my own body"; worried about losing his independence and about an operation; thinking clear and well organized; no depression or thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Tamsulosin 0.4 mg oral capsule, one capsule by mouth at bedtime
- S Finasteride 5 mg oral tablet, one tablet by mouth daily
- S Polyethylene glycol 3350, 17 g in water once daily as needed for constipation
- S Ceftriaxone 1 g intramuscularly, one dose in clinic
- S Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 6 days
- S Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for fever or discomfort
Procedures and immunizations
Procedures
- S Indwelling urethral catheter inserted (16 French, 10 mL balloon) with a leg bag and night bag; 680 mL drained; observed for two hours for post-obstructive diuresis, which did not occur
- S Ultrasound of both kidneys and the bladder: no hydronephrosis; kidneys normal in size; bladder wall trabeculated, catheter balloon in place; prostate about 85 mL with a modest median lobe
- S Change of urethral catheter before cultures for a febrile catheter-associated infection; urine culture taken from the new catheter
- S Trial without catheter after six weeks of tamsulosin: catheter removed in the early morning; voided small amounts; bladder scan 420 mL; catheter replaced
- S Second trial without catheter after four months of finasteride with tamsulosin: catheter removed in the early morning; voided 240 mL and 210 mL; bladder scan 150 mL; catheter left out
Immunizations
- S 2025-10-14: High-dose influenza vaccine, 2025-2026 season
- S 2026-06-09: Respiratory syncytial virus vaccine (adjuvanted), single dose
- S 2026-06-09: Pneumococcal conjugate vaccine PCV20
- S 2026-06-09: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D Late 1937: Loss of consciousness, comatose and near death for a time; the illness is not characterized further in the cited source (CLM-0005)
- D 15 September 1940: Severe lower abdominal pain with a severe urinary tract infection while visiting the hills at Kalimpong; brought back unconscious to Calcutta for treatment (CLM-0006)
Family history
- D natural daughter: Tuberculosis in young adulthood; died before him (cause of death not recorded in the cited source)
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Bladder drained and kidney function back to normal within two weeks | 2026-03-03 | completed | Creatinine 1.42 mg/dL at presentation, 1.18 mg/dL after two weeks of drainage; no hydronephrosis |
| No catheter-associated infection, or prompt treatment if one occurs | 2026-03-31 | completed | One febrile catheter-associated infection at four weeks, treated in clinic for 7 days without admission; resolved |
| A treatment decision that he understands and that fits his values, after a geriatric assessment, by about ten weeks | 2026-04-28 | completed | Chose to continue the catheter with tamsulosin and finasteride and to try again without the catheter after three to four months, deferring surgery; recorded in his own words |
| Voiding without a catheter, with a post-void residual under 300 mL, by about five months | 2026-07-14 | completed | Second trial without catheter succeeded: residual 150 mL, IPSS 13 |
| Goals of care and a health care agent recorded | 2026-06-09 | completed | Goals of care discussed at the ten-week visit; health care agent named and his wishes recorded at the wellness visit |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Evaluation: IPSS with the quality-of-life question, bladder scan for post-void residual, urinalysis and urine culture, blood count, creatinine and electrolytes, digital rectal examination, and a kidney and bladder ultrasound for obstruction; a frequency-volume chart once voiding | completed | GL-AUA-BPH-2021, GL-AUA-CUR-2017, GL-CMID-2026 |
| PSA only after shared decision-making: it helps estimate prostate size and choose treatment; screening for prostate cancer is not recommended at his age, and he would not want treatment for a slow-growing cancer; drawn before the catheter is placed, because retention and catheters raise it | completed | GL-AUA-BPH-2021, GL-USPSTF-PROSTATE-2018, GL-CMID-2026 |
| Indwelling urethral catheter to drain the bladder, with a closed drainage system, the bag below the bladder, daily washing with soap and water, no routine antibiotics or bladder washouts, no treatment of bacteria in the urine without symptoms, a change every four weeks, and same-day review for fever, pain, blood, or a blocked catheter | completed | GL-IDSA-CAUTI-2009, GL-AUA-CUR-2017 |
| Tamsulosin 0.4 mg at bedtime for at least three days and usually several weeks before a trial without catheter; fall precautions: take it after the evening meal, rise slowly, sit to pass urine at night, and use a night light | completed | GL-AUA-BPH-2021, GL-BEERS-2023 |
| Urology consultation for chronic urinary retention with a raised creatinine: confirm the cause, judge the risk, plan the trial without catheter, advise on a 5-alpha-reductase inhibitor, and set out the procedures that suit a frail 79-year-old who wants to avoid an operation | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017 |
| Medication review with the AGS Beers Criteria: avoid anticholinergic drugs for bladder symptoms while in retention, first-generation antihistamines, and benzodiazepines; avoid nonselective alpha-blockers; review his herbal preparation with the pharmacist for interactions and unlabeled ingredients | completed | GL-BEERS-2023, GL-AYUR-METALS-2008 |
| Monitor on the CMID and AUA schedule: IPSS at every visit once voiding; post-void residual with each trial without catheter and after it; creatinine with retention; PSA at baseline and six months after starting finasteride, doubled for interpretation; response to tamsulosin at four to twelve weeks and to finasteride at three to six months | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026 |
| Geriatric assessment before any surgical decision: frailty, gait and falls, orthostatic blood pressure on tamsulosin, cognition, mood, delirium risk, nutrition, and what matters most to him | completed | GL-BEERS-2023, GL-AUA-BPH-2021 |
| Finasteride 5 mg daily for the 85 mL prostate, with a new PSA baseline after six months (measured value doubled for interpretation); trial without catheter after about six weeks of tamsulosin, once any infection is treated | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026 |
| Surgical options counseled after the failed trial without catheter: laser enucleation (HoLEP) recommended for an 85 mL prostate with refractory retention; transurethral resection and simple prostatectomy as alternatives; prostatic artery embolization under local anesthesia as a less invasive option with less durable results; prostatic urethral lift and water vapor therapy less suitable for this size, median lobe, and retention; each weighed against his frailty, delirium risk, and wishes | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-BEERS-2023 |
| His decision, in his own terms: defer any operation or procedure; keep the catheter, changed every four weeks, with tamsulosin and finasteride; a second trial without catheter after three to four months of finasteride; reconsider prostatic artery embolization, then laser enucleation, if that fails or if infections recur, bleeding, stones, or kidney harm develop; continue his herbal preparation after the pharmacist's review | completed | GL-AUA-BPH-2021, GL-AUA-BPH-2023, GL-CMID-2026, GL-AUA-CUR-2017 |
Planned encounters
- 2026-02-17 — New-patient visit for a weak stream, straining, and frequent urination at night, with a feeling that the bladder does not empty (ENC-001)
- 2026-03-03 — Two-week review with kidney and bladder ultrasound results and urology consultation (ENC-002)
- 2026-03-17 — Same-day sick visit for fever with a urinary catheter (ENC-006, unscheduled)
- 2026-03-31 — Six-week review with a trial without catheter and a geriatric assessment (ENC-003)
- 2026-04-28 — Ten-week review: shared decision about treatment and goals of care (ENC-004)
- 2026-06-09 — Subsequent annual wellness visit (ENC-007)
- 2026-07-14 — Five-month review with a planned second trial without catheter (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Sick Visit
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Annual Wellness Visit, Subsequent
- Progress note 07 — Focused Visit (Care-plan review)
- Urology referral
- Urology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Sick Visit (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Annual Wellness Visit, Subsequent (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Urology referral (XML)
- Urology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Rabindranath Tagore: Biographical. From Nobel Lectures, Literature 1901-1967 | NobelPrize.org (Nobel Prize Outreach) | biography |
| SRC-0002 | The Nobel Prize in Literature 1913: Summary | NobelPrize.org (Nobel Prize Outreach) | other |
| SRC-0003 | Rabindranath Tagore | Wikipedia | other |
| SRC-0004 | History | Visva-Bharati | other |
| SRC-0005 | Maji S. Review of The Last Days of Rabindranath Tagore in Memoirs, translated and edited by Somdatta Mandal (2021). Gitanjali and Beyond, issue 9 | Scottish Centre of Tagore Studies (Gitanjali and Beyond) | scholarly |
| SRC-0006 | Mukherjee A. Rare exhibition gives insight into the last days of Bard of Bengal, Tagore | Asia Times | other |
| SRC-0007 | Dinda A. India pays homage to Tagore on his 75th death anniversary | Gulf News | other |
| SRC-0008 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the retention work-up, the PSA decision, catheter care and the infection treatment, the trials without catheter, finasteride, the surgical options for an 85 mL prostate in a frail man, the Beers review, and the recorded deviation. |
| provenance review | not_started | Nobel Prize biography and citation, Wikipedia, the Visva-Bharati history page, a journal review of five memoirs by women who nursed him, and two news reports of a 2016 exhibition and a 2018 reconstruction logged. The 1937 and 1940 illnesses, his preference for traditional treatment, his fear of the operation, its date, and his death are D; the enlarged prostate, the nature of the operation, the cause of death, and prostate cancer are R and conflict. No statement, decision, or health fact is attributed to a relative, caregiver, or historical physician in the modern episode. |
| safe messaging review | not_started | His death is recorded as a fact without detail. His reluctance about surgery and his trust in traditional medicine are recorded with respect, as documented. PHQ-2 is negative, so no safety assessment is required. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.